Shionogi seeks Japanese approval for a new lotion formulation of its atopic dermatitis drug, aiming to improve patient adherence and treatment outcomes.
The introduction of a lotion formulation for CORECTIM® addresses a practical need for atopic dermatitis patients, particularly for application on the scalp and other hairy areas. This user-centric formulation is designed to improve treatment adherence by offering a more cosmetically acceptable and convenient option than traditional ointments. Enhanced patient compliance could lead to better treatment outcomes and solidify Shionogi's market position in Japan's competitive dermatology sector.
The new formulation is expected to improve patient adherence and quality of life
Shionogi applies for Japanese approval of a new lotion form of its atopic dermatitis drug
This regulatory & policy sits within a broader pattern of healthtech & biotech activity across Japan markets.
0 new signals this week → 0% vs last week
Browse this channelShionogi is seeking Japanese approval for a new lotion formulation of its atopic dermatitis drug, designed for easier application and improved patient adherence. This user-centric approach aims to enhance treatment outcomes and strengthen Shionogi's position in the dermatology market.
Healthtech & Biotech
This signal belongs to the Healthtech & Biotech channel. Browse related signals to see how this development fits into the broader landscape.
149 signals in this channelSign in to save notes on signals.
Sign In